

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/N49504A12F72EN.html>

Date: June 2022

Pages: 62

Price: US\$ 3,500.00 (Single User License)

ID: N49504A12F72EN

Abstracts

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

According to the recently published report 'Nicotinamide Phosphoribosyl transferase – Drugs In Development, 2022'; Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes.

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) – Nicotinamide phosphoribosyltransferase (NAMPTase) is an enzyme encoded by the PBEF1 gene. This protein has also been reported to be a cytokine (PBEF) that promotes B cell maturation and inhibits neutrophil apoptosis. NAMPTase catalyzes the condensation of nicotinamide with 5-phosphoribosyl-1-pyrophosphate to yield nicotinamide mononucleotide, one step in the biosynthesis of nicotinamide adenine dinucleotide. The protein is an adipokine that is localized to the bloodstream and has various functions, including the promotion of vascular smooth muscle cell maturation and inhibition of neutrophil apoptosis. It also activates insulin receptor and has insulin-mimetic effects, lowering blood glucose and

improving insulin sensitivity.

The report 'Nicotinamide Phosphoribosyl transferase – Drugs In Development, 2022' outlays comprehensive information on the Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 9 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecule, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Toxicology, Cardiovascular, Central Nervous System, Gastrointestinal, Immunology and Respiratory which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Colorectal Cancer, Multiple Myeloma (Kahler Disease), Pulmonary Radiation Toxicity, Acute Lung Injury, Age Related Memory Impairment, Amyotrophic Lateral Sclerosis, Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome, Depression, Diffuse Large B-Cell Lymphoma, Ewing Sarcoma, Follicular Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Idiopathic Pulmonary Fibrosis, Inflammatory Bowel Disease, Leukemia, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Melanoma, Non-Alcoholic Steatohepatitis (NASH), Non-Hodgkin Lymphoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Parkinson's Disease, Peripheral T-Cell Lymphomas (PTCL), Primary Mediastinal B-Cell Lymphoma, Prostate Cancer, Pulmonary Arterial Hypertension, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Acute Myeloid Leukemia, Relapsed Chronic Lymphocytic Leukemia (CLL), Renal Cell Carcinoma, Solid Tumor, Systemic Lupus Erythematosus, Traumatic Brain Injury, Triple-Negative Breast Cancer (TNBC), Unspecified Cancer and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12)

The report reviews Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics and enlists all their major and minor projects

The report assesses Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) – Overview

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) – Companies Involved in Therapeutics

Development

AbbVie Inc

Aqualung Therapeutics Corp

Aurigene Discovery Technologies Ltd

Calico Life Sciences LLC

Eli Lilly and Co

Genentech USA Inc

Karyopharm Therapeutics Inc

OncoTartis Inc

Remedy Plan Inc

Tianjin Hemay Pharmaceutical Co Ltd

Valo Health LLC

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) – Drug Profiles

ALT-200 – Drug Profile

Product Description

Mechanism Of Action

AU-4869 – Drug Profile

Product Description

Mechanism Of Action

History of Events

enamptcumab – Drug Profile

Product Description

Mechanism Of Action

History of Events

GNE-617 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Hemay-088 – Drug Profile

Product Description

Mechanism Of Action

KPT-9274 – Drug Profile

Product Description

Mechanism Of Action

History of Events

LSN-3154567 – Drug Profile

Product Description

Mechanism Of Action

OPL-0021 – Drug Profile

Product Description

Mechanism Of Action

History of Events

OT-82 – Drug Profile

Product Description

Mechanism Of Action

History of Events

P7-C3A20 – Drug Profile

Product Description

Mechanism Of Action

History of Events

RP-216 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit NAMPT for Oncology – Drug Profile

Product Description

Mechanism Of Action

STF-118804 – Drug Profile

Product Description

Mechanism Of Action

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) – Dormant Products

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) – Discontinued Products

Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) – Product Development Milestones

Featured News & Press Releases

Apr 04, 2022: Aqualung Therapeutic's ALT-100 monoclonal antibody cited as a novel therapeutic for lung fibrosis

Feb 01, 2022: Aqualung Therapeutic's ALT-100 antibody significantly reduces ARDS severity in both rat and porcine (large animal) preclinical models

Jan 25, 2022: Preclinical studies show Aqualung Therapeutic's eNAMPT- targeting ALT-100 mAb to reduce severity of aggressive prostate cancer

Dec 07, 2021: CEO & Founder of Aqualung Therapeutics Joe G.N. Garcia MD to present corporate update at the Annual Biotech Showcase in San Francisco

Aug 23, 2021: Aqualung Therapeutics selected to present at the Phoenix 2021 Venture Madness Competition on October 6-7th

Jun 15, 2021: Aqualung Therapeutics plans A phase 0 ARDS trial for eNAMPT monoclonal antibody (Alt-100 mAb) following Type B FDA meeting

Apr 05, 2021: Antengene announces NMPA approval of IND application for ATG-019 in patients with advanced solid tumors or non-Hodgkin's lymphoma

Feb 11, 2021: eNAMPT, the inflammation-regulatory protein specifically targeted by aqualung therapeutic's monoclonal antibody ALT-100, is now tightly linked to outcomes in COVID-19 infected patients

Dec 02, 2020: Aqualung Therapeutics publication supports eNAMPT as both biomarker & therapeutic target in prostate cancer; prostate cancer KOL new addition to scientific advisory board

Oct 19, 2020: Researchers discover neuroprotective treatment for chronic traumatic brain injury

Jun 02, 2020: Aqualung Therapeutics receives A \$2.3 million National Institute Of Health (NIH) Fast-Track award to develop a novel therapeutic antibody for patients with radiation-induced lung injury

May 27, 2020: Aqualung Therapeutics receives NIH approval to advance to IND-enabling studies via the STTR Fastrack Phase II award for development of a novel anti-inflammatory therapeutic antibody for ARDS and the critically ill

Apr 13, 2020: Antengene announces dosing of first patient in the ATG-019 (KPT-9274)

phase 1 trial, a first-in-class dual inhibitor, for advanced solid tumors and non-hodgkin's lymphoma

Mar 18, 2020: Aqualung Therapeutics advances its investigational monoclonal antibody into IND-enabling studies of Acute Respiratory Distress Syndrome (ARDS) And Ventilator-Induced Lung Injury (VILI)

Jan 16, 2020: International research collaboration reveals promising drug candidate for treatment of blood cancers

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by AbbVie Inc, 2022
Pipeline by Aqualung Therapeutics Corp, 2022
Pipeline by Aurigene Discovery Technologies Ltd, 2022
Pipeline by Calico Life Sciences LLC, 2022
Pipeline by Eli Lilly and Co, 2022
Pipeline by Genentech USA Inc, 2022
Pipeline by Karyopharm Therapeutics Inc, 2022
Pipeline by OncoTartis Inc, 2022
Pipeline by Remedy Plan Inc, 2022
Pipeline by Tianjin Hemay Pharmaceutical Co Ltd, 2022
Pipeline by Valo Health LLC, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/N49504A12F72EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N49504A12F72EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970